文献速递胸部肿瘤

基于血浆T790M监测指导奥希替尼治疗在EGFR突变非小细胞肺癌患者中的研究:EORTC肺癌组1613 APPLE II期随机临床试验

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
PubMed 文献 · Ann Oncol · 2023-02-28

APPLE研究评估纵向血浆EGFR T790M监测指导吉非替尼与奥希替尼最佳序贯策略的可行性。B组18个月奥希替尼治疗中无进展生存率为67.2%(84%CI 56.4%-75.9%),C组为53.5%(84%CI 42.3%-63.5%),达到主要终点。B组17%患者基于ctDNA T790M突变在RECIST进展前切换至奥希替尼。

要点

  • B组18个月奥希替尼治疗中PFS率为67.2%,C组为53.5%,达到主要终点。
  • B组17%(8/47)患者基于ctDNA T790M突变在RECIST进展前切换至奥希替尼。
  • B组中位PFS为22.0个月,C组为20.2个月;B组中位OS未达到,C组为42.8个月。

核心结论

  • 在EGFR突变晚期非小细胞肺癌第一代EGFR抑制剂治疗期间纵向监测ctDNA T790M状态是可行的。
  • 在RECIST进展前的分子进展导致17%的患者更早切换至奥希替尼,且PFS和OS结果令人满意。

研究设计与样本

  • APPLE研究为随机、非比较性II期研究,纳入常见EGFR突变、未经治疗的非小细胞肺癌患者。
  • 研究分为三组:A组(一线奥希替尼至RECIST进展)、B组(吉非替尼至cobas EGFR检测v2发现ctDNA EGFR T790M突变或RECIST进展)、C组(吉非替尼至RECIST进展),后两组随后切换至奥希替尼。
  • 主要终点为B组随机化后18个月奥希替尼治疗中无进展生存率(PFSR-OSI-18),无效假设为≤40%。
  • 本报告为B组和C组的结果,2017年11月至2020年2月,B组随机52例,C组随机51例。

主要发现

  • B组中位分子进展时间为266天,17%(8/47)患者基于ctDNA T790M突变在RECIST进展前切换至奥希替尼。
  • B组18个月奥希替尼治疗中PFS率为67.2%(84%CI 56.4%-75.9%),C组为53.5%(84%CI 42.3%-63.5%)。
  • B组中位PFS为22.0个月,C组为20.2个月;B组中位OS未达到,C组为42.8个月。
  • B组中位脑PFS为24.4个月,C组为21.4个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The APPLE trial aimed to evaluate the feasibility of longitudinal plasma epidermal growth factor receptor (EGFR) T790M monitoring for the best sequencing strategy of gefitinib and osimertinib. METHODS: APPLE is a randomized, non-comparative, phase II study in patients with common EGFR-mutant, treatment-naive non-small-cell lung cancer including three arms: arm A (osimertinib upfront until RECIST progression, PD), arm B [gefitinib until emergence of circulating tumor DNA (ctDNA) EGFR T790M mutation by cobas EGFR test v2 or RECIST PD], and arm C (gefitinib until RECIST PD), and then switch to osimertinib in both arms. The primary endpoint is the progression-free survival (PFS) rate 'on osimertinib' at 18 months (PFSR-OSI-18) after randomization in arm B (H0: PFSR-OSI-18 of ≤40%). Secondary endpoints include response rate, overall survival (OS), and brain PFS. We report the results of arms B and C. RESULTS: From November 2017 to February 2020, 52 and 51 patients were randomized into arms B and C, respectively. Most patients were females (70%) and had EGFR Del19 (65%); one-third had baseline brain metastases. In arm B, 17% of patients (8/47) switched to osimertinib based on the emergence of ctDNA T790M mutation before RECIST PD, with a median time to molecular PD of 266 days. The study met its primary endpoint of PFSR-OSI-18 of 67.2% (84% confidence interval 56.4% to 75.9%) in arm B versus 53.5% (84% confidence interval 42.3% to 63.5%) in arm C, with a median PFS of 22.0 months versus 20.2 months, respectively. The median OS was not reached in arm B versus 42.8 months in arm C. Median brain PFS in arms B and C was 24.4 and 21.4 months, respectively. CONCLUSIONS: The serial monitoring of ctDNA T790M status in advanced EGFR-mutant non-small-cell lung cancer during treatment with first-generation EGFR inhibitors was feasible, and a molecular progression before RECIST PD led to an earlier switch to osimertinib in 17% of patients with satisfactory PFS and OS outcomes.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Remon J, Besse B, Aix SP, et al. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. Ann Oncol. 2023. PMID: 36863484. doi:10.1016/j.annonc.2023.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。